# A Phase II Study of 131I-rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma (DLBCL)

> **NCT01676558** · PHASE2 · UNKNOWN · sponsor: **Korea Cancer Center Hospital** · enrollment: 24 (estimated)

## Conditions studied

- Relapsed or Refractory Diffuse Large B Cell Lymphoma

## Interventions

- **DRUG:** 131I-rituximab

## Key facts

- **NCT ID:** NCT01676558
- **Lead sponsor:** Korea Cancer Center Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-06
- **Primary completion:** 2016-06
- **Final completion:** 2017-06
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2012-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01676558

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01676558, "A Phase II Study of 131I-rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma (DLBCL)". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01676558. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*